{
  "id": 18070878,
  "title": "Emcure Pharma shares hit 10% upper circuit as Q2 net profit rises",
  "url": "https://urgent.news/2026/11/04/emcure-pharma-shares-hit-10-upper-circuit-as-q2-net-profit-rises",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-04T04:56:19.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/emcure-pharma-shares-hit-10-upper-circuit-as-q2-net-profit-rises/article71663991.ece"
  },
  "original_language": "en",
  "account": "Emcure Pharmaceuticals shares surged by 10 percent on Wednesday, reaching the upper circuit following a substantial rise in its consolidated net profit for the September quarter. The company reported a 29.31 percent increase in its net profit to ₹325.06 crore, driven by robust performance in its international business. Brokerages responded positively to the company's financial results, maintaining their buy ratings and revising growth estimates. Jefferies, in particular, raised its target price for Emcure Pharma shares to ₹2,500, up from ₹2,320, and revised its FY27 revenue growth guidance to over 20 percent from the previous mid-teens projection. The brokerage also highlighted the company's expansion of Amphotericin B in 20 European countries and the upcoming launch of Treprostinil as key factors supporting the international business growth. Additionally, Kotak Mahindra Bank maintained its buy rating on Emcure Pharma with a target price of ₹2,450, raised its FY27 sales growth guidance to over 20 percent, and expects the company to achieve the upper end of its margin expansion guidance of 75-100 basis points. The brokerage expects a 19 percent compound annual growth rate (CAGR) in EPS over FY26-FY29, attributing this growth to domestic recovery, new product approvals, and deeper molecule penetration into the market.",
  "summary": "Emcure reported a 29.31% increase in consolidated net profit to ₹325.06 crore during the September quarter",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}